Peripheral neuropathy (PN) is present in 30-50% of individuals with Immunoglobulin M Monoclonal gammopathy of unknown significance (IgM MGUS) and Waldenstrom Macroglobulinemia (WM). In approximately 50% of these cases, this is due to IgM anti-myelin-associated glycoprotein (MAG) paraprotein-associated peripheral neuropathy (anti-MAG PN) 1, 2 . Anti-MAG PN typically presents as a chronic demyelinating disorder with progressive ataxia, tremor and sensory disturbance. The typical electrophysiological features associated with anti-MAG PN consist of slowed motor conduction velocities with a disproportionate prolongation of the distal motor latency, and significant involvement of sensory nerves. 1, 3 By definition, a serum IgM paraprotein and anti-MAG antibodies are present. Up to 50% of patients develop significant disability after 10-15 years. Progressive disease-related disability is an indication to start treatment. However, while there is some evidence supporting clinical benefit of rituximab, 1, 4 there is currently no consensus on the optimal treatment approach for anti-MAG PN and there is a high clinical need for effective therapies 1 .
IgM paraproteinemia is a hallmark of WM and IgM MGUS. WM is an indolent B-cell malignancy with lymphoplasmacytic differentiation typically localized in the bone marrow (BM), while IgM MGUS is defined as asymptomatic IgM paraproteinemia with < 10% BM infiltration by lymphoplasmacytic cells. 5 The term "IgM related disease" is reserved for IgM MGUS with symptoms that are attributable to the paraprotein, such as cryoglobulinaemia, neuropathy and cold agglutinin disease 5 . Individuals with IgM MGUS are at increased risk for developing B-cell malignancies, mainly
Recently, a recurrent somatic point mutation of the myeloid differentiation factor 88 (MYD88) gene, leading to an amino-acid change from leucine to proline (L265P), has been reported in the vast majority (> 90%) of WM patients and approximately 50% of IgM MGUS patients. The mutation is absent in healthy donors and multiple myeloma 8, 9 . MYD88 mutations, in particular the MYD88 L265P hot spot mutation, are found in a small subset of the aggressive large-cell B-cell lymphomas, including activated B-cell type diffuse large B-cell lymphoma and primary central nervous system lymphoma. 10, 11 . Among indolent small-cell B-cell lymphomas, the MYD88 L265P mutation is largely confined to WM. 8 MYD88 is an adaptor protein of the interleukin-1R and toll-like receptor signalling pathways that ultimately lead to activation of nuclear factor-κB (NF-κB) and Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3). The MYD88 L265P mutation results in aberrant activation of these pathways and is considered the central driver mutation of WM and a diagnostic signature of the disease. In individuals with IgM MGUS, the presence of MYD88 L265P is associated with a higher risk of progression to WM 7 . In WM patients, treatment with ibrutinib, an oral Bruton's Tyrosine Kinase (BTK) inhibitor is less effective in WM patients with wild-type MYD88 than in those with MYD88 L265P 12 . The incidence of MYD88 L265P is unknown in most IgM related disorders, with the exception of cold agglutinin disease (CAD), a chronic hemolytic disorder associated with IgM paraproteinemia. In CAD, MYD88 L265P was absent in all tested patients, which confirmed it as a distinct entity from WM. 13 Thus far, the mutational status of MYD88 has not been studied in IgM related PN. In the current study, we have found a high prevalence of MYD88 L265P in the BM of anti-MAG PN-patients. MYD88 L265P mutation analysis was performed at two centres (UCLH and AMC) on DNA extracted from either stored BM aspirates or trephine biopsy specimens, using an allele specific PCR as described previously 10 . In samples that tested negative for the mutation, the presence of a B-cell clone was assessed using multiplex PCRs for the detection of B-cell receptor rearrangements 14 .
The clinical characteristics of the patients, including neurological findings and relevant biochemical parameters, as well as the results of the mutation analysis are summarized in table 1. The MYD88 L265P mutation was detected in 13/22 patients (59%). Of the 9 patients (41%) that tested negative for the mutation, the presence of a B-cell clone was confirmed by rearrangement testing in 2 patients. In the other 7 patients that tested negative for the mutation, a clonal B cell population could not be detected.
Our study demonstrates that the MYD88 L265P mutation is highly prevalent in a cohort of well-characterized anti-MAG PN patients. The detected mutational rate of 59% most likely represents an underestimate since the tumour load was generally very low, as shown by the low quantity of clonal B-cells as detected by flow cytometry and negative B-cell receptor rearrangement-based clonality studies in 7/9 mutation negative patients. This indicates a very low frequency of neoplastic B cells in these samples, which may have precluded MYD88 L265P detection. Indeed, the reported prevalence of MYD88 L265P in IgM MGUS is highly variable (10-87%) which most likely relates to sensitivity issues in the setting of a low clonal B-cell burden. 
